Adaptive Biotechnologies Income Statement (2018-2026) | ADPT

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	38.51M	39.47M	37.93M	38.62M	43.66M	47.83M	55.20M	37.65M	7.70M	37.92M	45.78M	41.87M	43.19M	46.44M	47.46M	52.44M	58.88M	93.97M	71.68M	70.87M
Cost of Revenue (Quarter)	10.77M	14.19M	14.36M	13.19M	13.22M	14.91M	16.59M	18.68M	17.91M	19.35M	19.62M	18.05M	19.32M	16.67M	18.05M	16.98M	18.00M	18.16M	18.22M	18.71M
Gross Profit (Quarter)	27.74M	25.28M	23.57M	25.43M	30.44M	32.92M	38.61M	18.97M	-10.21M	18.57M	26.17M	23.82M	23.87M	29.77M	29.41M	35.46M	40.88M	75.82M	53.46M	52.17M
Operating items
Amortization - Intangibles (Quarter)	0.42M	0.43M	0.43M	0.42M	0.42M	0.43M	0.43M	0.42M	0.42M	0.43M	0.43M	0.42M	0.42M	0.43M	0.43M	0.42M	0.42M	0.43M	0.43M	0.42M
Research & Development (Quarter)	23.22M	36.07M	26.70M	26.09M	37.04M	35.66M	31.22M	32.60M	32.24M	28.53M	55.44M	22.32M	20.31M	24.16M	5.00M	24.20M	24.13M	23.47M	21.76M	26.35M
Selling, General & Administrative (Quarter)	16.07M	20.15M	23.35M	24.14M	21.20M	20.75M	22.43M	20.83M	22.30M	20.07M	20.73M	19.60M	17.89M	17.26M	18.06M	17.40M	17.79M	17.96M	19.56M	20.98M
Restructuring Costs (Quarter)												1.04M	0.68M	0.19M	0.09M					0.64M
Other Operating Expenses (Quarter)	48.99M	39.57M	49.48M	51.45M	37.92M	36.85M	40.73M	41.41M	42.20M	40.27M	40.68M	47.67M	51.62M	37.45M	58.16M	40.45M	41.99M	42.25M	43.13M	42.11M
Operating Expenses (Quarter)	88.27M	95.79M	99.53M	101.69M	96.16M	93.26M	94.38M	94.84M	96.74M	88.88M	116.85M	90.64M	90.51M	79.07M	81.30M	82.05M	83.92M	83.68M	84.45M	90.08M
Operating Income (Quarter)	-49.77M	-56.33M	-61.60M	-63.07M	-52.50M	-45.43M	-39.19M	-57.19M	-47.82M	-50.96M	-71.07M	-48.76M	-47.32M	-32.63M	-33.84M	-29.60M	-25.04M	10.29M	-12.77M	-19.21M
EBIT (Quarter)	-49.77M	-56.33M	-61.60M	-63.07M	-52.50M	-45.43M	-39.19M	-57.19M	-47.82M	-50.96M	-71.07M	-48.76M	-47.32M	-32.63M	-33.84M	-29.60M	-25.04M	10.29M	-12.77M	-19.21M
Non-operating items
Interest & Investment Income (Quarter)	0.46M	0.33M	0.24M	0.27M	0.42M	0.77M	2.60M	3.02M	3.61M	4.28M	4.61M	4.22M	3.77M	3.47M	3.07M	2.68M	2.39M	2.23M	2.15M	2.08M
Net income details
EBT (Quarter)	-350.09M	-274.17M	-64.06M	-208.69M	-66.18M	-48.85M	-38.88M	-57.70M	-47.81M	-50.33M	-69.47M	-48.24M	-46.25M	-32.10M	-31.00M	-29.93M	-123.26M	9.54M	-14.44M	-53.00M
Tax Provisions (Quarter)
Profit After Tax (Quarter)	-56.00M	-56.00M	-61.45M	-62.74M	-52.08M	-45.32M	-40.17M	-57.70M	-47.81M	-50.33M	-69.44M	-47.53M	-46.22M	-32.07M	-33.72M	-29.83M	-25.61M	9.54M	-13.62M	-20.02M
Income from Non-Controlling Interests (Quarter)		-0.10M	0.08M	-0.06M	-0.04M	-0.04M	-0.04M	-0.00M	-0.00M	-0.03M	-0.03M	-0.03M	-0.03M	-0.03M	-0.03M	0.02M	0.02M	-0.00M		0.02M
Income from Continuing Operations (Quarter)	-350.09M	-274.17M	-64.06M	-208.69M	-66.18M	-48.85M	-38.88M	-57.70M	-47.81M	-50.33M	-69.47M	-48.24M	-46.25M	-32.10M	-31.00M	-29.93M	-123.26M	9.54M	-14.44M	-53.00M
Consolidated Net Income (Quarter)	-350.09M	-274.17M	-64.06M	-208.69M	-66.18M	-48.85M	-38.88M	-57.70M	-47.81M	-50.33M	-69.47M	-48.24M	-46.25M	-32.10M	-31.00M	-29.93M	-123.26M	9.54M	-14.44M	-53.00M
Income towards Parent Company (Quarter)	-350.09M	-274.17M	-64.06M	-208.69M	-66.18M	-48.85M	-38.88M	-57.70M	-47.81M	-50.33M	-69.47M	-48.24M	-46.25M	-32.10M	-31.00M	-29.93M	-123.26M	9.54M	-14.44M	-53.00M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-350.09M	-274.17M	-64.06M	-208.69M	-66.18M	-48.85M	-38.88M	-57.70M	-47.81M	-50.33M	-69.47M	-48.24M	-46.25M	-32.10M	-31.00M	-29.93M	-123.26M	9.54M	-14.44M	-53.00M
Additional items
EPS (Basic) (Quarter)	-2.49	-1.95	-0.46	-1.47	-0.46	-0.34	-0.27	-0.40	-0.33	-0.35	-0.48	-0.33	-0.31	-0.22	-0.21	-0.20	-0.81	0.06	-0.10	-0.34
EPS (Diluted) (Quarter)	-2.49	-1.95	-0.46	-1.47	-0.46	-0.34	-0.27	-0.40	-0.33	-0.35	-0.48	-0.33	-0.31	-0.22	-0.21	-0.20	-0.81	0.06	-0.10	-0.34
Shares Outstanding (Quarter)	140.36M	140.83M	140.35M	141.70M	142.36M	142.93M	142.52M	143.51M	144.40M	144.70M	144.38M	145.79M	147.41M	147.52M	147.10M	149.20M	152.08M	152.43M	151.72M	155.52M
Shares Outstanding (Diluted) (Quarter)	140.36M	140.83M	140.35M	141.70M	142.36M	142.93M	142.52M	143.51M	144.40M	144.70M	144.38M	145.79M	147.41M	147.52M	147.10M	149.20M	152.08M	163.16M	151.72M	155.52M
Shares Outstanding (Entity) (Quarter)	140.66M	141.03M	141.39M	142.18M	142.78M	142.99M	143.11M	144.28M	144.65M	144.77M	145.08M	147.37M	147.46M	147.56M	147.77M	151.92M	152.23M	152.58M	153.78M	159.70M
EBITDA (Quarter)	-49.77M	-56.33M	-61.60M	-63.07M	-52.50M	-45.43M	-39.19M	-37.10M	-24.82M	-29.83M	2.90M	-28.18M	-11.29M	-11.33M	-6.55M	-9.22M	-6.07M	6.96M	13.25M	12.14M
Interest Expenses (Quarter)	300.79M	218.17M	2.70M	145.89M	14.10M	4.18M	2.30M	3.53M	3.60M	3.65M	3.01M	3.70M	2.70M	2.94M	0.24M	3.00M	100.61M	2.97M	3.81M	35.88M
Tax Rate (Quarter)

Research Tools

Developers

Adaptive Biotechnologies Income Statement (2018-2026) | ADPT

Research Tools

Developers

Adaptive Biotechnologies Income Statement (2018-2026) | ADPT

Create an account

Sign In

Reset Password